Viz.ai, a groundbreaking company specializing in disease detection and intelligent care coordination, has made remarkable strides in the field of cardiovascular health. The recent approval of the company’s hypertrophic cardiomyopathy (HCM) technology by the U.S. Food and Drug Administration (FDA) heralds a new era of AI-enabled notification software for cardiovascular conditions.
Hypertrophic cardiomyopathy, a devastating disease that often remains undetected until it is too late, affects around one million people in the U.S. Shockingly, only 20% of these individuals have been diagnosed. However, early detection and treatment can dramatically improve longevity and quality of life, as HCM is the leading cause of sudden cardiac death in persons under the age of 35.
With Viz.ai’s innovative platform, healthcare providers can identify and diagnose more patients with suspected HCM earlier. By utilizing the power of machine learning to scan medical images from across a health system, the algorithm can detect both obstructive and non-obstructive HCM. The result? Patients receive prompt access to the appropriate cardiology specialists, and the care team can swiftly review the patient’s electrocardiogram (ECG), coordinate follow-up procedures such as an echocardiogram, and access critical images and reports through the Viz mobile application.
Viz.ai’s HCM artificial intelligence module is just one of the twelve FDA-cleared algorithms featured on their comprehensive enterprise-wide AI platform. Developed with an immense dataset consisting of more than 830,000 ECG exams from 300,000 individuals worldwide, the algorithm has been financially supported through a multi-year agreement with Bristol Myers Squibb.
The FDA’s approval of Viz.ai’s HCM technology underscores a larger trend in the healthcare industry – the evolution of regulatory and approval processes for AI-enabled tools. The FDA’s De Novo pathway, designed for low- to moderate-risk devices seeking marketing authorization, has facilitated the advancement of AI technology in healthcare.
Q: What is hypertrophic cardiomyopathy?
A: Hypertrophic cardiomyopathy (HCM) is a cardiovascular disease characterized by the thickening of heart muscle, which makes it harder for the heart to pump blood efficiently.
Q: How does Viz.ai’s AI-enabled technology aid in the detection of HCM?
A: Viz.ai’s innovative platform uses machine learning to scan medical images and identify signs of HCM, allowing healthcare providers to diagnose and treat patients earlier.
Q: How many people in the U.S. have HCM?
A: Approximately one million people in the U.S. are affected by hypertrophic cardiomyopathy.
Q: What is the potential impact of AI technology in cardiology?
A: AI technology has the potential to significantly improve cardiology care by enhancing disease detection, streamlining care coordination, and ultimately improving health outcomes.